-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 58c, provides guidance
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 1c, provides guidance
-
-
-
-
-
-
-
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
-
-
-
-
-
-
-
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
-
-
-
-
-
-
-
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Reports Preliminary 2023 Revenue, 2024 Guidance
-
-
-
-
-
-
-
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

